Table 1.
Enrichment of IPA® canonical pathways.
| Ingenuity canonical pathways | –log (B-H p-value) | B-H p-value | Ratio | Molecules |
|---|---|---|---|---|
| Granulocyte adhesion and diapedesis | 5.87 | 1.35E-06 | 0.0791 | CXCL9, CCL7, IL1B, CXCL10, CXCL8, HSPB1, CCL22, MMP19, HRH4, CXCL1, CSF3, CXCL3, CXCL5, MMP1 |
| Role of IL-17A in psoriasis | 4.75 | 1.78E-05 | 0.385 | S100A9, CXCL1, CXCL3, CXCL5, CXCL8 |
| Granulocyte adhesion and diapedesis | 4.2 | 6.31E-05 | 0.0635 | CXCL9, CCL22, CCL7, MMP19, IL1B, CXCL10, CXCL1, CXCL3, CXCL5, MMP1, ITGB7, CXCL8 |
| Hepatic fibrosis/hepatic stellate cell activation | 3.63 | 0.000234 | 0.0601 | CCR7, CXCL9, IL1B, VEGFA, CD14, MET, COL4A4, CXCL3, COL18A1, MMP1, CXCL8 |
| Role of IL-17F in allergic inflammatory airway diseases | 3.58 | 0.000263 | 0.136 | CCL7, IL1B, CXCL10, CXCL1, CXCL5, CXCL8 |
| Role of IL-17A in arthritis | 3.58 | 0.000263 | 0.104 | CCL7, PTGS2, CXCL1, CXCL3, CXCL5, MMP1, CXCL8 |
| Differential regulation of cytokine production in macrophages and T helper cells by IL-17A and IL-17F | 2.95 | 0.001122 | 0.222 | IL9, IL1B, CXCL1, CSF3 |
| Airway pathology in chronic obstructive pulmonary disease | 2.72 | 0.001905 | 0.375 | CXCL3, MMP1, CXCL8 |
| Differential regulation of cytokine production in intestinal epithelial cells by IL-17A and IL-17F | 2.61 | 0.002455 | 0.174 | IL9, IL1B, CXCL1, CSF3 |
| Th1 and Th2 activation pathway | 2.43 | 0.003715 | 0.0486 | GATA3, DLL1, IL9, ICOS, IL24, LTA, CCR4, MAF, CCR3 |
| Th2 pathway | 2.38 | 0.004169 | 0.0533 | GATA3, DLL1, IL9, ICOS, IL24, CCR4, MAF, CCR3 |
| IL-17 signaling | 2.26 | 0.005495 | 0.0706 | CXCL10, PTGS2, CXCL1, IL19, CXCL5, CXCL8 |
| Role of tissue factor in cancer | 2.24 | 0.005754 | 0.0574 | GNAQ, IL1B, VEGFA, CXCL1, MMP1, CXCL8, P4HB |
| Communication between innate and adaptive immune cells | 2.21 | 0.006166 | 0.0674 | CCR7, TNFRSF17, IL1B, CXCL10, TNFRSF13B, CXCL8 |
| Oncostatin M signaling | 2.16 | 0.006918 | 0.118 | CHI3L1, MT2A, EPAS1, MMP1 |
| Inhibition of matrix metalloproteases | 1.95 | 0.01122 | 0.103 | MMP19, ADAM12, TFPI2, MMP1 |
| Role of hypercytokinemia/hyperchemokinemia in the pathogenesis of influenza | 1.82 | 0.015136 | 0.093 | IL9, IL1B, CXCL10, CXCL8 |
| IL-17A signaling in gastric cells | 1.54 | 0.02884 | 0.12 | CXCL10, CXCL1, CXCL8 |
| Bladder cancer signaling | 1.54 | 0.02884 | 0.0575 | MMP19, VEGFA, THBS1, MMP1, CXCL8 |
| Role of cytokines in mediating communication between immune cells | 1.54 | 0.02884 | 0.0741 | IL1B, IL24, CSF3, CXCL8 |
| Unfolded protein response | 1.54 | 0.02884 | 0.0741 | HSPA5, XBP1, DNAJB9, P4HB |
| Intrinsic prothrombin activation pathway | 1.42 | 0.038019 | 0.103 | THBD, F5, COL18A1 |
| Pathogenesis of multiple sclerosis | 1.39 | 0.040738 | 0.222 | CXCL9, CXCL10 |